Call us today: +1 (304) 470-2225
You can use WPML or Polylang and their language switchers in this area.


IDHI Mutation AML

How Acute myeloid leukaemia (AML) Clinical Landscape is transforming for IDH1 or IDH2 mutated patients? Key comments from ASH 2022

Acute myeloid leukaemia is a genetically heterogeneous hematologic malignancy in which approximately 8% and 12% of acute myeloid leukemias harbour an IDH1 or IDH2 mutation, respectively.  A generally inferior outcome is seen with IDH1 mutations […]

Read More